Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CNSWG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN106188293A ADC-13
|
|||||
| Synonyms |
CN106188293A_ADC 13
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Hepatocellular carcinoma [ICD11:2C12]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Antibody Name |
Anti-MET mAb Ab-11
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
CN106188293A_ADC-13LacNAc-based glycosite-specific conjudate through reduced inter-chain cysteines
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.